Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Aileron Therapeutics (NASDAQ: ALRN) reported its Q1 2024 financial results, highlighting positive data from Cohort 1 of its Phase 1b trial for LTI-03 in idiopathic pulmonary fibrosis (IPF) patients. The trial showed statistical significance in three out of eight biomarkers, with promising safety and tolerability. Topline results from Cohort 2 are expected in Q3 2024. The company raised approximately $20 million from a direct offering in May 2024, potentially adding another $20 million from warrant exercises. Cash reserves were $12 million as of March 31, 2024, expected to fund operations into H2 2025. R&D expenses rose to $3.5 million from $1.8 million YoY, primarily due to the acquisition of Lung. G&A expenses increased to $3.7 million from $2.2 million. Net loss for the quarter was $7.1 million, compared to $4.8 million in Q1 2023.
- Positive data from Cohort 1 of Phase 1b trial for LTI-03 in IPF, with statistical significance in 3 out of 8 biomarkers.
- No serious adverse events reported in the Phase 1b trial, indicating good safety and tolerability of LTI-03.
- Topline results from Cohort 2 expected in Q3 2024, potentially boosting investor confidence.
- Raised approximately $20 million from a direct offering in May 2024, enhancing financial flexibility.
- Potential to raise an additional $20 million from the exercise of warrants issued in the offering.
- Cash reserves of $12 million as of March 31, 2024, expected to fund operations into H2 2025.
- R&D expenses increased to $3.5 million from $1.8 million YoY, primarily due to the acquisition of Lung, reflecting higher operational costs.
- G&A expenses increased to $3.7 million from $2.2 million, driven by higher professional fees and employee-related expenses.
- Net loss for Q1 2024 was $7.1 million, up from $4.8 million in Q1 2023, indicating a widening financial deficit.
Insights
The recent financial results from Aileron Therapeutics are a mixed bag with some bright spots. The company reported a net loss of $7.1 million for Q1 2024, an increase from the
Cash reserves are currently at
While the increased R&D and G&A expenses reflect their active progression in clinical trials and operational expansion, the financials indicate a need for watchfulness. Investors should consider both the potential of their clinical programs and the company's ability to manage ongoing expenses.
The clinical progress reported by Aileron Therapeutics is quite promising. In the Phase 1b trial for LTI-03 targeting idiopathic pulmonary fibrosis (IPF), positive trends were observed in seven out of eight biomarkers, with three reaching statistical significance. This is significant because biomarkers are indicators that can provide early signs of disease progression or therapeutic effect.
IPF is a debilitating condition with limited treatment options, making any positive data noteworthy. The fact that LTI-03 was well-tolerated with no serious adverse events (SAEs) reported further strengthens the case for its potential. Importantly, the stimulation of solRAGE is notable as it suggests an impact on type I epithelial cell health, which is important in IPF management.
With topline results from a high-dose cohort expected in the third quarter, there is an upcoming catalyst that could further validate the efficacy and safety profile of LTI-03. However, investors should remain cautious about the early-phase nature of this data and the subsequent need for larger, more definitive trials.
The financial and clinical updates from Aileron Therapeutics provide a nuanced outlook for potential investors. On one hand, the recent underwritten registered direct offering that raised approximately
The positive Phase 1b data for LTI-03 in IPF patients has the potential to significantly impact the company's market position. The IPF market is projected to grow, driven by advancements in treatment and increasing disease awareness. Positive trends in early-stage trials could enhance Aileron's competitive edge, especially as they target an orphan disease area with high unmet needs.
Yet, the market should also consider the timing and feasibility of additional funding rounds, given that the current cash position supports operations only into the second half of 2025. It’s essential for retail investors to weigh the balance between clinical promise and financial sustainability when considering Aileron’s stock.
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated
Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in the third quarter of 2024
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
“In the first quarter, we made steady progress against our key priorities of advancing LTI-03 and generating data from Cohort 1 in IPF,” said Brian Windsor, Ph.D., President and Chief Executive Officer of Aileron. “We are encouraged that low dose LTI-03 achieved statistical significance in three out of eight biomarkers evaluated in the trial, along with promising safety and tolerability that reinforce the potential of LTI-03 to improve lung function and reverse the course of the disease. We expect to report topline results from Cohort 2 in the ongoing Phase 1b study in the third quarter of this year.”
First Quarter 2024 Highlights and Recent Updates
Financing and Management Updates
- In May 2024, the Company closed on an underwritten registered direct offering of 4,273,505 shares of its common stock and accompanying warrants to purchase an aggregate of 4,273,505 shares of common stock resulting in aggregate gross proceeds to the Company of approximately
$20 million , before deducting underwriting discounts and commissions and other offering expenses payable by the Company, and excluding any proceeds that may be received from exercise of the warrants. Each share of common stock and accompanying warrant were sold together at a combined public offering price of$4.68 T he exercise of the warrants issued in the offering has the potential to result in additional proceeds to the Company of up to approximately$20 million . - In March 2024, the Company announced the appointment of Brian Windsor, Ph.D., as President and Chief Executive Officer and to the Board of Directors. Dr. Windsor previously served as the Company’s Chief Operating Officer and President, and Chief Executive Officer and director of Lung Therapeutics, Inc. (“Lung”).
Pipeline
- Announced positive Cohort 1 data from the Phase 1b clinical trial evaluating the safety and tolerability of inhaled LTI-03 in patients diagnosed with IPF.
- Following inhaled administration of low dose LTI-03 (2.5 mg BID, or twice daily) in twelve patients, a positive trend was observed in seven out of eight biomarkers with evidence of reduced expression among profibrotic proteins produced by basal-like cells and fibroblasts that contribute to the progression of IPF, including data from three out of eight biomarkers that were statistically significant, reinforcing the potential of LTI-03 to improve lung function and reverse the course of IPF.
- LTI-03 was also found to stimulate production of solRAGE, a factor indicative of type I epithelial cell health that is a critically important aspect of IPF and has gone largely unaddressed. Results show LTI-03 to be generally well-tolerated with no serious adverse events (SAEs) reported.
- The Phase 1b study is ongoing, with topline results from the high-dose cohort expected in the third quarter of 2024.
- On May 1, 2024, the Company hosted a pulmonary care expert call to discuss the Cohort 1 Phase 1b results of LTI-03, featuring pulmonary care expert Andreas Günther, M.D., Head of the Center for Interstitial and Rare Lung Diseases at the Justus Liebig University in Giessen, Germany. A replay of the event can be accessed at https://investors.aileronrx.com/events-presentations/investor-events.
First Quarter 2024 Financial Results
- Cash Position: Cash and cash equivalents on March 31, 2024, were
$12.0 million , compared to$17.3 million on December 31, 2023. After including the net proceeds raised from the May 2024 offering and based on its current operating plan, the Company expects its existing cash and cash equivalents to fund operations into the second half of 2025. - Research and Development (R&D) Expenses: R&D expenses for the quarter ended March 31, 2024, were
$3.5 million , compared to$1.8 million for the quarter ended March 31, 2023. The increase of$1.7 million was primarily a result of the Company’s acquisition of Lung in October 2023. During the quarter ended March 31, 2024, Aileron spent$1.1 million on clinical trials,$1.6 million on manufacturing, and$0.2 million on regulatory and development consulting as well as$0.6 million on employee and related expenses related to Lung’s programs acquired as a result of the Company’s acquisition of Lung in October 2023. These activities did not exist during the quarter ended March 31, 2023 and were offset by the termination of ALRN-6924 activities during the quarter ended March 31, 2023. - General and Administrative (G&A) Expenses: G&A expenses for the quarter ended March 31, 2024, were
$3.7 million compared to$2.2 million for the quarter ended March 31, 2023. The increase of$1.5 million was primarily due to increased professional fees of$1.0 million and increased employee and related expenses of$0.3 million in the quarter ended March 31, 2024 as compared to the quarter ended March 31, 2023. The majority of the increase related to the acquisition of Lung, which closed in October 2023. - Net Loss: Net loss for the quarter ended March 31, 2024, was
$7.1 million , compared to$4.8 million for the corresponding quarter in 2023. The basic and diluted net loss per share for the quarter ended March 31, 2024 was$0.86 compared to$1.05 for the quarter ended March 31, 2023.
About Aileron Therapeutics
Aileron Therapeutics, Inc. is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron’s lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis. Aileron’s second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US.
Forward-Looking Statements
This press release may contain forward-looking statements of Aileron within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to: the timing and expectation of the topline results from Cohort 2 of the Phase 1b study of LTI-03; the sufficiency of the Company’s cash resources; the projected cash runway of the Company; the status and plans for clinical trials, including the timing of data; future product development; and the potential commercial opportunity of LTI-03 and LTI-01. We use words such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “would,” “can,” “could,” “should,” “continue,” and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties related to: the Company’s ability to maintain the listing of its common stock on The Nasdaq Capital Stock Market; changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in the Company’s drug discovery; preclinical and clinical development activities; the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials or that partial results of a trial such as the Cohort 1 results from the Company’s ongoing Phase 1b trial may not be indicative of the full results of the trial; the Company’s ability to enroll patients in its clinical trials; and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all; decisions made by the U.S. Food and Drug Administration and other regulatory authorities; investigational review boards at clinical trial sites and publication review bodies with respect to the Company’s development candidates; competition; the sufficiency of the Company’s cash resources to fund its planned activities for the periods anticipated and the Company’s ability to manage unplanned cash requirements; and general economic and market conditions; as well as the risks and uncertainties discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2024, which are on file with the United States Securities and Exchange Commission (the “SEC”) and in subsequent filings that the Company files with the SEC. These forward-looking statements should not be relied upon as representing the Company’s view as of any date subsequent to the date of this press release, and we expressly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Relations & Media Contact:
Argot Partners
aileron@argotpartners.com
212-600-1902
| Aileron Therapeutics, Inc. | |||||||
| Balance Sheet Data | |||||||
| (Unaudited) | |||||||
| (In thousands) | |||||||
| March 31, 2024 | December 31, 2023 | ||||||
| Cash and cash equivalents | $ | 12,042 | $ | 17,313 | |||
| Working capital | 8,232 | 13,881 | |||||
| Total assets | 99,192 | 106,008 | |||||
| Accumulated deficit | (295,630 | ) | (288,517 | ) | |||
| Total stockholders' equity | $ | 44,750 | $ | 6,887 | |||
| Aileron Therapeutics, Inc. | |||||||
| Condensed Consolidated Statement of Operations | |||||||
| (Unaudited) | |||||||
| (In thousands, except share and per share data) | |||||||
| Three Months Ended March 31, | |||||||
| 2024 | 2023 | ||||||
| Revenue | $ | - | $ | - | |||
| Operating expenses: | |||||||
| Research and development | 3,463 | 1,810 | |||||
| General and administrative | 3,742 | 2,179 | |||||
| Restructuring and other costs | - | 1,022 | |||||
| Total operating expenses | 7,205 | 5,011 | |||||
| Loss from operations | (7,205 | ) | (5,011 | ) | |||
| Other income (expense), net | 92 | 232 | |||||
| Net loss | (7,113 | ) | (4,779 | ) | |||
| Net loss per share — basic and diluted | $ | (0.86 | ) | $ | (1.05 | ) | |
| Weighted average common shares outstanding—basic and diluted | 8,301,798 | 4,541,167 | |||||
FAQ
What were the financial results for Aileron Therapeutics in Q1 2024?
What were the key findings from the Cohort 1 Phase 1b trial for LTI-03 in IPF patients?
When are the topline results from Cohort 2 of the LTI-03 trial expected?
How much capital did Aileron Therapeutics raise in May 2024?
What is the expected funding period for Aileron Therapeutics' operations with current cash reserves?
